Post-exercise Insulin Reductions in Type 1 Diabetes

The Metabolic and Glycaemic Responses to Reductions in Rapid-acting Insulin Dose After Running Exercise in People With Type 1 Diabetes Mellitus.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01531855

Enrollment

Registered

2012-02-13

Start date

2012-02-29

Completion date

2012-08-31

Last updated

2014-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

T1DM, Exercise

Brief summary

The investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent Type 1 diabetes individuals experiencing hypoglycaemia.

Interventions

OTHERReducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose

Dosage after exercise

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* T1DM, * Male, * basal-bolus regimen (insulin glargine / detemir with insulin lispro / aspart), * HbA1c \< 9.9%, * aged 18-50.

Exclusion criteria

* HbA1c \> 10%, * not treated with basal-bolus (insulin glargine / detemir with insulin lispro / aspart), * aged \<18 \> 50.

Design outcomes

Primary

Measure	Time frame	Description
24 hour blood glucose area under the curve	24 hours	24 hour, post-exercise, glucose area under the curve.

Secondary

Measure	Time frame	Description
Ketogenesis	60 minutes before and 24 hours post-exercise	Blood beta-hydroxybutyrate concentrations

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026